Three-Year Data Showed Low Incidence Of BARACLUDE® (Entecavir) Resistance In Nucleoside-Naïve Chronic Hepatitis B Patients

... Bristol-Myers Squibb Company (NYSE: BMY) today announced three-year results of the BARACLUDE® (entecavir) resistance monitoring program, which found the incidence of resistance to be low among patients treated with BARACLUDE in nucleoside-naïve studies (n=673). Two patients, or less than one percent, experienced viral rebound due to BARACLUDE resistance through week 144. [click link for full article] ...